CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

BACKGROUND: Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple factors, including general efficacy, tolerability, potential for serious adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandervorst, Fenne, Van Deun, Laura, Van Dycke, Annelies, Paemeleire, Koen, Reuter, Uwe, Schoenen, Jean, Versijpt, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547103/
https://www.ncbi.nlm.nih.gov/pubmed/34696711
http://dx.doi.org/10.1186/s10194-021-01335-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547103/
https://www.ncbi.nlm.nih.gov/pubmed/34696711
http://dx.doi.org/10.1186/s10194-021-01335-2

Ejemplares similares